these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.
As of May 9, 2019, we have 491,138,042 outstanding shares of common stock. Of these outstanding shares, all of the shares sold in the
IPO, the November 2018 secondary offering and the March 2019 secondary offering are, and all of the shares to be sold under the registration statement of which this prospectus forms a part will be, immediately tradable without restriction under the
Securities Act of 1933, as amended, or the Securities Act, except for any shares held by affiliates, as that term is defined in Rule 144 under the Securities Act, or Rule 144.
In May 2018, November 2018 and March 2019, we filed registration statements on Form
S-8
under the
Securities Act to register the shares of common stock to be issued under our equity compensation plans and, as a result, all shares of common stock acquired upon exercise of stock options granted under our plans are also freely tradable under the
Securities Act, subject to the terms of the
lock-up
agreements, unless purchased by our affiliates. As of May 9, 2019, 5,557,380 shares of our common stock are available for future issuances under our
equity incentive plans.
The remaining shares of common stock outstanding as of May 9, 2019 are restricted securities within the
meaning of Rule 144, but will be eligible for resale subject, in certain cases, to applicable volume, manner of sale, holding period and other limitations of Rule 144 or pursuant to an exception from registration under Rule 701 under the
Securities Act, or Rule 701, subject to the terms of applicable
lock-up
agreements.
In the future, we may issue additional shares of common stock or other equity or debt securities convertible into or exercisable or
exchangeable for shares of our common stock in connection with a financing, strategic investment, litigation settlement or employee arrangement or otherwise. Any of these issuances could result in substantial dilution to our existing stockholders
and could cause the trading price of our common stock to decline.
If securities or industry analysts do not publish research or
publish misleading or unfavorable research about our business, our stock price and trading volume could decline.
The trading
market for our common stock depends in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts that cover our common stock downgrade our stock or publish misleading or
unfavorable research about our business, our stock price would likely decline. If one or more of the analysts ceases coverage of our common stock or fails to publish reports on us regularly, demand for our common stock could decrease, which could
cause our common stock price or trading volume to decline.
Future offerings of debt or equity securities which would rank senior to
our common stock may adversely affect the market price of our common stock.
If, in the future, we decide to issue debt or equity
securities that rank senior to our common stock, it is likely that such securities will be governed by an indenture or other instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable
securities that we issue in the future may have rights, preferences and privileges more favorable than those of our common stock and may result in dilution to owners of our common stock. We and, indirectly, our stockholders, will bear the cost of
issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature
of our future offerings. Thus, holders of our common stock will bear the risk of our future offerings reducing the market price of our common stock and diluting the value of their stock holdings in us.
13